What Cofafer Treats: Main Uses and Benefits

Cofafer is generally used for the management of documented iron deficiency, a condition characterized by a shortage of iron necessary for creating oxygen-carrying red blood cells. This injection is commonly reserved for cases where oral iron administration has been unsatisfactory or impossible.

The medication is commonly used to help treat Severe Iron Deficiency Anemia (IDA) that is chronic or unresponsive to oral supplements. It is relevant in scenarios involving iron malabsorption, such as in patients with Inflammatory Bowel Disease (IBD) or following bariatric surgery, as well as in individuals with certain chronic conditions like Non-Dialysis Dependent Chronic Kidney Disease (CKD). The therapeutic domain focuses on patients with a significant lack of iron necessary for making oxygen-carrying blood cells. By addressing the underlying deficit, Cofafer helps to relieve debilitating symptom clusters, including pronounced chronic fatigue, reduced physical endurance, and specific neurological issues like Restless Legs Syndrome or pica. This use provides supportive benefit when the primary absorption pathway is compromised.

“This treatment helps ease the overall symptomatic burden and may assist with maintaining day-to-day comfort.”

Quick Fact: Relief for Anemia Symptoms
Symptom Focus	Profound fatigue, physical weakness, and reduced stamina associated with low oxygen transport.
Therapeutic Benefit	Supports the replenishment of iron stores necessary for managing the anemia and easing functional strain.
Context	Applied when oral iron is not feasible due to malabsorption or patient intolerance.

Regulatory References

1. Iron Dextran Injection: MedlinePlus Drug Information

Cofafer's eligibility is strictly defined by regulatory documents, allowing its use only when oral iron therapy is unfeasible, ineffective, or contraindicated. The medicine is primarily approved for adults and pediatric patients age 4 months and older who have documented iron deficiency.

Contraindicated Populations

Patients must not use Cofafer if they have:

• Known hypersensitivity to iron dextran or any component.
• Existing iron overload (e.g., hemosiderosis or haemochromatosis).
• Anemias that are not associated with iron deficiency (e.g., hemolytic anemia).
• The acute phase of infectious kidney disease.

Age and Condition Restrictions

Use is not recommended for infants under 4 months of age, as safety and effectiveness have not been established in this population. Use must proceed with extreme caution in patients with serious liver function impairment. Conditional use with caution is also required for those with pre-existing cardiovascular disease, rheumatoid arthritis, or a history of significant allergies or asthma.

Pregnancy and Lactation Status

For pregnancy, the medicine is classified as Category C, meaning its use is restricted to cases where the potential benefit justifies the potential risk. Treatment is generally confined to the second or third trimester. Caution is advised for nursing mothers, as trace amounts of the drug may be excreted into human milk.

Interactions with other medicines and products

Official regulatory documentation identifies specific medicinal products, classes, and diagnostic tests that interact with Iron Dextran (Cofafer), requiring strict management or procedural awareness.

---

Documented Drug and Substance Interactions

Interacting Substance/Class	Official Interaction Statement	Restriction Classification
Oral Iron Preparations	Reduces the gastrointestinal absorption and therapeutic effect of the oral iron product.	Restricted Concomitant Use
ACE Inhibitors (e.g., Enalapril, Lisinopril)	Concomitant use may increase the patient's risk for an anaphylactic-type reaction.	Use with Caution/Increased Risk

---

Timing and Procedural Constraints

1. Oral Iron Therapy Separation: Oral iron therapy must not be initiated earlier than five days after the final injection of Cofafer to prevent interference with the oral product's absorption.
2. Diagnostic Test Interference: Iron Dextran formally interferes with certain clinical diagnostic tests. Large doses may cause falsely elevated values for serum bilirubin and falsely decreased values for serum calcium.
3. Serum Iron Determination: Serum iron concentration assays, particularly colorimetric assays, may not yield meaningful results for up to three weeks following the administration of Cofafer.
4. Bone Scan Results: The injection can interfere with ^99 m Tc-labeled bone scans, potentially causing reduced bony uptake and excessive soft tissue accumulation.

---

Note on Population-Specific Interactions: Official regulatory labels do not specify that the severity of these documented interactions is differentially heightened or unique to a specific patient population, such as those with hepatic impairment or the elderly.

How Cofafer Works

The action of Cofafer (Iron Dextran) is centered on the rapid, controlled delivery of elemental iron ( Fe^3+), acting as a prodrug that directly augments the iron metabolism and oxygen transport systems. Its mechanism differs from conventional receptor-based pharmacology by focusing on nutrient substrate provision.

---

Specialized Delivery via the Reticuloendothelial System

Cofafer's high-molecular-weight colloidal complex is rapidly engulfed by specialized immune cells known as macrophages within the Reticuloendothelial System (RES). These cells internally process the complex through endocytosis and slowly cleave the Dextran shell to liberate the iron via controlled enzymatic degradation. This controlled release mechanism restricts the rate of iron dissociation, maintaining stability during systemic distribution and minimizing the immediate formation of free iron.

---

Direct Augmentation of Iron Homeostasis and Transport

Once released from the macrophages, the iron immediately binds to the body's main transport protein, Transferrin, thereby augmenting the circulating functional iron pool. This mechanism provides a significant increase in the circulating iron supply, bypassing the slow, tightly regulated absorption process of the gut. The physiological effect is an efficient, targeted supply of the essential substrate to the body's storage sites (Ferritin) and utilization centers.

---

Substrate Provision for the Erythropoiesis Cascade

The transported iron is delivered specifically to Erythroid Precursors in the bone marrow, where it is incorporated into the Heme structure of the Hemoglobin molecule. This direct provision increases the rate of the final steps of red blood cell maturation. The core physiological consequence is a direct increase in the blood's oxygen transport capacity, directly linked to the synthesis of Hemoglobin molecules.

How to use Cofafer: Administration Guidelines

Established guidelines define the required steps and dosing rules for the correct use of Cofafer. Adherence to these instructions structures the complete treatment course.

---

Administration Requirements

Guideline	Instruction
Route of Administration	Oral (by mouth)
Dosing Schedule (Adults)	One tablet
Frequency and Timing	Once daily, at approximately the same time each day
Meal Condition	Must be taken with food
Preparation	None (tablet is taken whole)

---

Procedural and Missed Dose Instructions

The full procedure for administration is standardized:

1. Take one tablet of Cofafer.
2. Administer the dose by mouth.
3. Take the tablet with food.
4. Consume the dose at approximately the same time each day.

Missed Dose Protocol:

If a daily dose is forgotten, the instructions dictate the following action: take the dose as soon as it is remembered, unless the time is less than 12 hours before the next scheduled dose. In this specific case, the missed dose should be skipped, and the regular daily schedule should be resumed.

These instructions define the operational structure for administering the medicine and completing the therapeutic course.

Research evidence / Overview of studies for Cofafer

---

Evidence for Iron Deficiency Anemia Unresponsive to Oral Iron

Research into Cofafer (Iron Dextran) has focused on patients diagnosed with Iron Deficiency Anemia (IDA) who were enrolled in studies because they had not responded well to, or could not tolerate, taking iron supplements by mouth. The evidence base includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that evaluate intravenous iron delivery against oral supplements or standard care.

Studies were conducted over time intervals ranging from a few weeks up to several months. Researchers primarily monitored shifts in key biomarkers: Hemoglobin (Hb) levels and Ferritin and Transferrin Saturation (TSAT), which are used to assess iron status. The findings describe patterns observed where patients receiving the injectable treatment had measurable increases in both their Hemoglobin and iron storage levels. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly.

---

Evidence for Anemia with Malabsorption or Chronic Conditions

Cofafer was evaluated in specific patient populations where conditions, such as Inflammatory Bowel Disease (IBD) or post-bariatric surgery status, affect the body's ability to absorb nutrients. Studies monitored outcomes related to systemic or functional imbalance, such as changes in Hemoglobin, as well as patient-reported outcomes describing perceived discomfort. The data describe patterns related to the changes measured in iron biomarkers in these cohorts.

---

Research in Specific Subgroups, Including Pregnancy

Cofafer was evaluated in pregnant women who had documented IDA and were enrolled due to oral iron failure or intolerance, primarily during the second and third trimesters. Research described patterns related to maternal outcomes, including changes in Hemoglobin levels before delivery and the rate of blood transfusions. The product was also evaluated in some pediatric patients who met specific criteria for severe IDA. Comparative evidence is lacking for certain study designs, and data for some groups remain insufficient.

---

Evidence Gaps and Areas of Uncertainty

While research describes the product's use in patients who need to alter their iron status, long-term effects are not fully established. Follow-up durations were limited in many key trials, meaning the data available provide limited insight into the need for future treatment cycles. Findings were sometimes varied in studies comparing Iron Dextran directly against other intravenous iron products.

Key Studies & References

1. Intravenous or oral iron for treating iron deficiency anaemia during pregnancy: systematic review and meta-analysis
2. Iron management in chronic kidney disease (KDIGO Guideline Excerpt)

Common questions about Cofafer (FAQ)

Q: Is it safe to store Cofafer in the refrigerator?

According to official product information, unopened vials of Cofafer are required to be stored at controlled room temperature, which is typically maintained between 15 C and 30 C (59 F and 86 F). The product should also be protected from freezing, as freezing can compromise the solution's integrity.

Q: Does Cofafer affect my ability to operate a car or machinery (cause drowsiness)?

Official regulatory documents list adverse effects such as dizziness and seizure as rare reactions to Cofafer. Because these effects could potentially affect motor skills or alertness, caution is noted in regulatory information regarding activities like operating a car or machinery.

Q: Is Cofafer safe to use for anemia that is not caused by iron deficiency?

The medicine is contraindicated for patients with anemias that are not associated with iron deficiency (for example, hemolytic anemia), meaning its use is restricted in these cases. Cofafer is designed to address deficiencies in the body's iron supply, which is why official regulatory documents state it should not be used for other types of anemia.

Q: Can I give Cofafer to my 2-year-old child if they have severe iron deficiency?

Official labeling for Cofafer specifies that it is approved for pediatric patients age 4 months and older who have documented iron deficiency. Safety and effectiveness have not been established in infants under 4 months of age, and use is generally restricted in this specific population.

Cofafer, which is a trade name for Iron Dextran injection, must be stored and disposed of according to strict official regulatory guidelines.

Storage Conditions

The unopened vials must be stored at controlled room temperature, typically maintained between 15 C and 30 C (59 F and 86 F). The product must be protected from freezing, as freezing can compromise the solution's integrity. If the vial is a multi-dose type, some labels require the remaining contents to be used within a limited period, such as 90 days after the first puncture.

Handling and Disposal

The medicine must always be kept out of the reach of children. Before use, the solution must be visually inspected for particulate matter. Any unused product or waste material must be disposed of in accordance with local requirements. Official guidance advises against flushing medicines down the toilet or drain unless explicitly instructed by the label. Needles and syringes must be placed immediately into a designated sharps container.